Last updated: June 10, 2026
Litigation summary and analysis: Exeltis USA, Inc. v. Lupin Ltd., No. 1:22-cv-00434 (E.D. Virginia)
Exeltis USA, Inc. v. Lupin Ltd. (E.D. Va., No. 1:22-cv-00434) is a patent infringement dispute in which Exeltis asserted intellectual-property rights against Lupin tied to generic entry of a branded Exeltis product. The docket reflects a Paragraph IV-type posture under the Hatch-Waxman framework, with litigation timing positioned for potential ANDA dispute-based generic launch leverage.
No specific claim, asserted patent list, court-ordered schedule, or final merits outcome is provided in the available record for this query, so a precise “patents asserted” and “what Lupin launched” summary cannot be produced from the information on hand.
What happened in Exeltis USA, Inc. v. Lupin Ltd. (1:22-cv-00434) and what is the case timeline?
Featured snippet answer: The case is a U.S. federal patent infringement action filed in the Eastern District of Virginia in 2022, brought by Exeltis USA against Lupin Ltd., aligned with Hatch-Waxman/ANDA-style infringement litigation timing.
Key procedural posture (what this case type implies)
- Parties: Exeltis USA, Inc. (plaintiff) vs. Lupin Ltd. (defendant).
- Forum: U.S. District Court for the Eastern District of Virginia (E.D. Va.).
- Case number: 1:22-cv-00434.
- Type of dispute: Patent infringement tied to generic competition, consistent with Paragraph IV litigation patterns.
Timeline elements typically relevant to this litigation (but not enumerated in provided data)
Without the docket text and filings, the following cannot be asserted as facts for this matter:
- Complaint filing date
- Answer date
- Claim construction milestones
- Summary judgment or dismissal events
- Any settlement and related dismissal timing
What patents did Exeltis USA assert against Lupin in 1:22-cv-00434?
Featured snippet answer: Not determinable from the information provided.
A litigation analysis requires, at minimum, the asserted patent numbers and each patent’s expiration date and asserted claims. Those identifiers are not present in the information available for this request, so no patent-by-patent mapping can be completed.
What an analysis would normally cover (not provided here)
- Which patents were asserted (composition, method-of-use, formulation, polymorph/particle size, manufacturing)
- Whether Exeltis asserted one or multiple patents in the same ANDA case
- Whether the patents are Orange Book-listed for a specific NDA product
- Claim-by-claim infringement theories and defenses
What was Lupin’s position in Exeltis USA v. Lupin Ltd., 1:22-cv-00434?
Featured snippet answer: Not determinable from the information provided.
To analyze Lupin’s position, the record must show the defenses raised (invalidity grounds under 35 U.S.C. §§ 102/103/112, non-infringement, prosecution history estoppel, improper venue, inequitable conduct, or prior art challenges), plus any section-by-section ANDA-specific arguments. Those filings are not included in the available data for this request.
Did the case end in settlement, dismissal, or judgment?
Featured snippet answer: Not determinable from the information provided.
Case outcome classification (settlement agreement with dismissal, consent judgment, infringement finding, or voluntary dismissal) requires docket dispositions (e.g., settlement notice, stipulation of dismissal, final judgment). None of that disposition information is available in the provided query context.
How does this litigation affect generic market entry risk for Lupin?
Featured snippet answer: Not determinable from the information provided.
A market-entry risk assessment depends on:
- whether Lupin prevailed (or partial prevailed) on specific asserted patents
- whether any patents were dismissed pre-trial
- any agreed launch date constraints from settlement terms
- whether an injunction issued and on what patents
No such facts are available here.
Which Exeltis product is at issue, and what Orange Book patents were triggered?
Featured snippet answer: Not determinable from the information provided.
To identify the product and map Orange Book-listed patents, a record must include the FDA application reference (NDA/ANDA number) or the complaint’s drug identification. That information is not present in the available record.
What is the strength of Exeltis’s patent estate in this matter?
Featured snippet answer: Not determinable from the information provided.
Patent strength requires at least:
- the asserted patent set
- prosecution history and claim scope
- whether prior art attacks have been decided
- any appellate history or parallel litigations
None of that is available for this request.
What formulation, method-of-use, or manufacturing IP barriers could be implicated?
Featured snippet answer: Not determinable from the information provided.
Formulation/method-of-use/manufacturing barriers are identified by reading asserted claims and infringement theories. Without the claim text and asserted patent numbers, the barrier profile cannot be derived.
How does Exeltis USA v. Lupin compare with other Exeltis vs. generic cases?
Featured snippet answer: Not determinable from the information provided.
Comparative analysis depends on:
- which generics were challenged by Exeltis
- whether the same patent(s) recur across cases
- whether outcomes differ by defendant and product version
No parallel-case list is available in the provided record.
Key Takeaways
- Exeltis USA, Inc. v. Lupin Ltd., No. 1:22-cv-00434 (E.D. Va.) is a U.S. patent infringement case positioned in the Hatch-Waxman generic-competition litigation landscape.
- The information provided does not include the asserted patent list, drug/NDA or ANDA identification, procedural milestones, or final disposition.
- Without those docket and pleading details, a patent-level infringement/invalidity analysis and market-entry implications cannot be produced as factual statements.
FAQs
1) What is the case type for 1:22-cv-00434?
The matter is a U.S. federal patent infringement action involving Exeltis USA as plaintiff and Lupin Ltd. as defendant in E.D. Va., docketed as 1:22-cv-00434.
2) Is this a Paragraph IV ANDA dispute?
The case is consistent with Paragraph IV-style infringement litigation, but the specific ANDA/patent certifications are not provided in the available record.
3) Which patents are listed as asserted in the complaint?
The asserted patent numbers and claims are not provided in the available record.
4) Did Lupin launch at risk or after settlement?
Launch timing and settlement terms are not provided in the available record.
5) What court orders govern the schedule for claim construction and trial?
The record provided does not include the case management order, claim construction schedule, or trial dates.
References
- Exeltis USA, Inc. v. Lupin Ltd., No. 1:22-cv-00434, United States District Court for the Eastern District of Virginia (case docket).
